House of Lords Issues Report on Genomics; GenoMed Part of It


David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9938

ST. LOUIS—July 7, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that it is part of a white paper which the House of Lords Subcommittee on Genomics and Medicine issued today.

The House of Lords Committee on Science and Technology, Subcommittee on Genomic Medicine, issued a white paper today which encourages the National Health Service to make use of the advances in genomic medicine sooner rather than later (

GenoMed contributed to this report (, identifying specific ways in which any patient population could take advantage of what’s already known about genomic medicine.

David W. Moskowitz, MD FACP, GenoMed’s CEO, said “We’re delighted to have our contribution included in the House of Lords’ White Paper. As the pioneer in bringing genomic medicine to the clinic, GenoMed is in a unique position to improve patient outcomes and lower healthcare costs. Our program to eliminate dialysis around the world by 2014 is a perfect example (”

Added Dr. Moskowitz, “I hope the British National Health Service, as well as Medical Directors in charge of patient populations everywhere, read the House of Lords’ White Paper. Together, we can make our dream of eliminating 90% of kidney failure in 5 years a reality.”

About GenoMed

GenoMed is a Next Generation Disease Management company that aims to deliver the best patient outcomes at the lowest possible cost. As the only Public Health Company™ in the world, GenoMed aims to arrest diabetes, hypertension, and emphysema globally. No genotyping is required for these diseases. Please contact Dr. Moskowitz if you have one of these diseases.

About the House of Lords

The House of Lords began phasing out life-time, hereditary membership under the leadership of Prime Minister Tony Blair, and replacing peers with experts who had achieved distinction in their respective fields. This has enabled the House of Lords to provide expert advice to the House of Commons and the Executive Branch of British government, including the National Health Service.

Safe Harbor Statement

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) finances and treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.